Toronto Stock Exchange Symbol: MS
EDMONTON, Aug. 1 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has completed patient recruitment in its phase III clinical trial of MBP8298 (dirucotide) for the treatment of secondary progressive MS (SPMS). The trial, named MAESTRO-03, includes approximately 510 patients, and is being conducted at 68 trial sites in the U.S.
"We have had great success in recruiting patients into the trial, which
is a testament to the promise of our approach and the efforts of our
investigators," said Mr. Kevin Giese, President and CEO. "Since initiating
this trial in June 2007 we have been delighted by the enthusiasm of the
patients and clinical groups participating across the U.S."
MBP8298 (dirucotide) is currently being developed in three late-stage clinical trials:
1. MAESTRO-01: A pivotal phase II/III trial for secondary progressive MS
(SPMS) patients in Canada and Europe.
2. MAESTRO-03: A pivotal phase III trial for SPMS patients in the United
3. MINDSET-01: A phase II trial for relapsing-remitting MS (RRMS)
patients in Europe.
The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 68 clinical sites who will be administered either MBP8298 (dirucotide) or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).
About MBP8298 (dirucotide)
|SOURCE BioMS Medical Corp.|
Copyright©2008 PR Newswire.
All rights reserved